A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Talimogene laherparepvec (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Basal cell cancer; Colorectal cancer; Gastric cancer; HER2 negative breast cancer; Liver cancer; Liver metastases; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Skin cancer; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms MASTERKEY-318
- Sponsors Amgen
Most Recent Events
- 10 Mar 2025 Results evaluating intrahepatic T-VEC+pembrolizumab published in the Oncologist.
- 03 Sep 2023 This trial has been completed in belguim and Poland, according to European Clinical Trials Database record.
- 11 Jul 2023 Status changed from active, no longer recruiting to completed.